Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
1 day ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
1 day ago · The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant improvements in lung function ...
Dupixent approved in the US as the first-ever biologic medicine …
Sep 27, 2024 · Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis.
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Nov 7, 2024 · SNY. REGN. The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use ...
Press Release: Dupixent approved in the EU as the first and only ...
Nov 6, 2024 · Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis. Approval based on phase 3 data showing significantly more children aged one to 11 years ...
Press Room - Sanofi US News
Sep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic ...
Nov 7, 2024 · Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential and offering new hope for young ...
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
May 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease …
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
1 day ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
- Some results have been removed